Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib and Vorinostat with Gem/Bu/Mel and ASCT in Relapsed/Refractory Myeloma
NCT02114502Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2014
- Primary completion
- Sep 2018
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Classical Binding Small Molecules
01
Overview
A Phase 2 trial of carfilzomib, vorinostat in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2014; status: withdrawn.
02
Drugs
carfilzomibvorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02114502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114502.